Cardiovascular Drugs Practice Questions

Q: What is the intravenous treatment for Torsades de pointes?

Magnesium. **Explanation:** **1. Why Magnesium is the Correct Answer:** Intravenous **Magnesium Sulfate (MgSO₄)** is the drug of choice for **Torsades de Pointes (TdP)**, a polymorphic ventricular tachycardia associated with a prolonged QT interval. Magnesium works by stabilizing the cardiac membrane and inhibiting **Early Afterdepolarizations (EADs)**. It blocks the L-type calcium channels, thereby reducing the influx of calcium that triggers the abnormal triggered activity responsible for TdP. Notably, it is effective even in patients with normal baseline serum magnesium levels. **2. Why Other Options are Incorrect:** * **Sodium Bicarbonate:** This is the treatment of choice for **Tricyclic Antidepressant (TCA) overdose** or severe metabolic acidosis. While TCA overdose can cause QT prolongation, sodium bicarbonate acts by increasing extracellular sodium and alkalinizing the blood, not by directly treating the TdP rhythm. * **Saline (Normal Saline):** Used for volume expansion and fluid resuscitation. It has no anti-arrhythmic properties. * **Glucose (Dextrose):** Used to treat hypoglycemia. While combined with insulin it treats hyperkalemia, it has no role in managing TdP. **3. High-Yield Clinical Pearls for NEET-PG:** * **Dosage:** The standard dose is **2g IV bolus**, followed by an infusion if necessary. * **Mechanism of TdP:** It is often caused by drugs that block **K+ channels** (Class IA and III anti-arrhythmics) or electrolyte imbalances (Hypokalemia, Hypomagnesemia, Hypocalcemia). * **Alternative Treatment:** If MgSO₄ fails and the patient is stable, **Overdrive Pacing** or **Isoproterenol** (to increase heart rate and shorten the QT interval) can be used. If the patient is unstable, immediate **unsynchronized cardioversion** (defibrillation) is required.

Q: All of the following are ECG changes seen in Digoxin toxicity except?

PR shortening. ### Explanation **Digoxin** has complex effects on the cardiac conduction system, primarily mediated through increased vagal tone and direct inhibition of the Na+/K+ ATPase pump. **Why PR shortening is the correct answer:** Digoxin **increases vagal (parasympathetic) tone**, which slows conduction through the Atrioventricular (AV) node. On an ECG, AV nodal delay is manifested as **PR interval prolongation**, not shortening. In cases of toxicity, this can progress to various degrees of heart block. **Analysis of Incorrect Options:** * **QT shortening (A):** Digoxin shortens the ventricular action potential duration and the refractory period, leading to a characteristic **shortened QT interval**. This is a classic finding. * **ST depression (C):** One of the most common signs of digoxin effect/toxicity is **ST-segment depression** with a unique morphology known as the "reverse tick," "scooped-out," or "Salvador Dali mustache" appearance. * **T wave inversion (D):** Digoxin causes changes in ventricular repolarization, frequently resulting in **T wave flattening or inversion**, often associated with the ST-segment changes mentioned above. **High-Yield Clinical Pearls for NEET-PG:** * **Most common arrhythmia in toxicity:** Ventricular Bigeminy. * **Most characteristic/specific arrhythmia:** Atrial Tachycardia with AV block. * **Electrolyte triggers:** Hypokalemia, Hypomagnesemia, and Hypercalcemia predispose to toxicity. * **Visual disturbance:** Xanthopsia (yellow-green halos around lights). * **Antidote:** Digoxin-specific antibody fragments (DigiFab).

Q: Which of the following drugs should not be used empirically in the management of isolated systolic hypertension in the elderly?

Prazosin. **Explanation:** **Isolated Systolic Hypertension (ISH)**, defined as SBP ≥140 mmHg with DBP <90 mmHg, is common in the elderly due to age-related arterial stiffness. The primary goal of treatment is to reduce stroke and cardiovascular events without causing significant orthostatic hypotension. **Why Prazosin is the correct answer:** Prazosin is a selective **Alpha-1 blocker**. It is not recommended as first-line empirical therapy for ISH because it is associated with a high risk of **orthostatic (postural) hypotension** and "first-dose phenomenon." In elderly patients, whose baroreceptor reflexes are already blunted, this significantly increases the risk of syncope, falls, and fractures. Furthermore, the ALLHAT trial demonstrated that alpha-blockers are less effective than diuretics in preventing heart failure. **Why the other options are incorrect:** * **Chlorthalidone (Thiazide-like Diuretic):** Historically the "gold standard" for ISH. Large trials (SHEP trial) proved that low-dose thiazides significantly reduce stroke risk in the elderly. * **Amlodipine (Calcium Channel Blocker):** Long-acting DHP-CCBs are highly effective in ISH because they directly reduce peripheral vascular resistance and arterial stiffness. * **Enalapril (ACE Inhibitor):** ACE inhibitors (or ARBs) are preferred first-line agents, especially if the patient has co-morbidities like diabetes mellitus or chronic kidney disease. **High-Yield Clinical Pearls for NEET-PG:** * **First-line for ISH:** Thiazide diuretics (Chlorthalidone/Indapamide) or Long-acting DHP-CCBs (Amlodipine). * **Prazosin Indication:** Primarily used for Benign Prostatic Hyperplasia (BPH) or as add-on therapy in resistant hypertension. * **Side Effect Profile:** Always warn elderly patients about the risk of "first-dose syncope" with Alpha-blockers; advise taking the medication at bedtime.

Q: Which of the following statements about ezetimibe is true?

Inhibitor of NPCIL 1. **Explanation:** **Correct Option: C (Inhibitor of NPC1L1)** Ezetimibe is a lipid-lowering drug that selectively inhibits the absorption of dietary and biliary cholesterol from the small intestine. Its primary molecular target is the **Niemann-Pick C1-Like 1 (NPC1L1) protein**, a transport protein located on the brush border of intestinal enterocytes. By blocking this transporter, ezetimibe reduces the delivery of intestinal cholesterol to the liver, leading to an upregulation of hepatic LDL receptors and a subsequent decrease in circulating LDL-C levels. **Incorrect Options:** * **A (CETP Inhibitor):** Cholesteryl ester transfer protein inhibitors (e.g., Torcetrapib, Anacetrapib) work by preventing the transfer of cholesterol from HDL to LDL/VLDL, thereby increasing HDL levels. * **B (PPAR alpha inhibitor):** Fibrates (e.g., Fenofibrate) are PPAR-alpha **agonists** (not inhibitors), which increase the expression of lipoprotein lipase to lower triglycerides. * **D (PPAR Gamma inhibitor):** PPAR-gamma **agonists** (e.g., Pioglitazone) are used in Type 2 Diabetes to improve insulin sensitivity; they are not the target for ezetimibe. **High-Yield Clinical Pearls for NEET-PG:** * **Synergistic Effect:** Ezetimibe is frequently used as an "add-on" to **Statin therapy** because they have complementary mechanisms (Statins inhibit cholesterol synthesis, while Ezetimibe inhibits absorption). * **Effect on Lipids:** It primarily lowers **LDL (by ~18-20%)**, with minimal effects on HDL or Triglycerides. * **Side Effects:** Generally well-tolerated; however, when combined with statins, there is a slight risk of increased hepatic transaminases. * **Key Contraindication:** Active liver disease (especially when used with statins).

Q: A 69-year-old man with heart failure and paroxysmal atrial fibrillation is prescribed amiodarone for maintenance of sinus rhythm. Which of the following is a known characteristic of amiodarone?

An active metabolite. **Explanation:** Amiodarone is a unique Class III antiarrhythmic drug with a complex pharmacokinetic profile, making it a high-yield topic for NEET-PG. **Why Option C is Correct:** Amiodarone is extensively metabolized in the liver by the CYP3A4 enzyme. Its primary metabolite is **Desethylamiodarone (DEA)**. This metabolite is pharmacologically **active** and possesses electrophysiological properties similar to the parent drug, contributing significantly to its long-term therapeutic and toxic effects. **Analysis of Incorrect Options:** * **A. Excellent oral absorption:** While amiodarone is absorbed from the GI tract, its bioavailability is inconsistent and incomplete (ranging from 30% to 70%) due to significant first-pass metabolism. * **B. A short half-life:** Amiodarone is highly lipophilic and sequesters in tissues (fat, liver, lungs). It has an exceptionally **long elimination half-life**, typically ranging from **25 to 60 days**. This necessitates the use of loading doses. * **D. Few drug interactions:** Amiodarone is a potent **inhibitor** of several P450 enzymes (CYP2C9, CYP2D6, CYP3A4) and P-glycoprotein. It has numerous clinically significant interactions, most notably increasing the plasma concentrations of **Warfarin, Digoxin, and Statins**. **NEET-PG High-Yield Pearls:** * **Iodine Content:** Amiodarone is structurally related to thyroxine and contains 37% iodine by weight, leading to thyroid dysfunction (Hypothyroidism/Wolff-Chaikoff or Hyperthyroidism/Jod-Basedow). * **Adverse Effects:** Remember the "6 P's": **P**ulmonary fibrosis (most serious), **P**hotodermatitis (Blue-grey skin), **P**rolonged QT interval (though rarely causes Torsades), **P**eripheral neuropathy, **P**apillary deposits (corneal microdeposits), and **P**roximally-acting thyroid issues. * **Drug of Choice:** It is the preferred antiarrhythmic for patients with heart failure or structural heart disease.

Q: Which beta-blocker can be safely used in hepatic disease?

Esmolol. **Explanation:** The correct answer is **Esmolol (Option A)**. The primary medical concept here is the site of drug metabolism. **Why Esmolol is the correct choice:** Esmolol is a unique, ultra-short-acting $\beta_1$-selective blocker. Unlike most beta-blockers that undergo hepatic metabolism, Esmolol is rapidly hydrolyzed by **red blood cell (RBC) esterases**. Because its clearance is independent of liver or kidney function, it can be safely used in patients with hepatic failure without the risk of drug accumulation or toxicity. **Analysis of Incorrect Options:** * **Betaxolol (Option B):** This is a cardioselective beta-blocker that undergoes significant hepatic metabolism. It is not the preferred choice in liver disease. * **Bisoprolol (Option C):** Bisoprolol is balanced in its elimination (50% hepatic and 50% renal). While safer than purely hepatic drugs, it still requires caution and potential dose adjustment in severe liver disease compared to Esmolol. * **Carvedilol (Option D):** This is a non-selective beta and alpha-1 blocker that is **extensively metabolized by the liver**. It is contraindicated or requires extreme caution in patients with hepatic impairment due to a significant increase in bioavailability and half-life. **High-Yield Clinical Pearls for NEET-PG:** * **Esmolol Half-life:** Approximately **9 minutes**, making it ideal for "on-off" control during hypertensive emergencies or intraoperative tachycardia. * **Metabolism Fact:** Always remember "Esmolol = Esterases." This is a frequent examiner favorite. * **Propranolol:** It has high lipid solubility and undergoes extensive first-pass metabolism in the liver; it is the drug of choice for preventing variceal bleeding in portal hypertension but must be dosed carefully. * **Atenolol & Nadolol:** These are primarily **renally excreted** and are the drugs of choice when avoiding hepatic metabolism is necessary, though Esmolol remains the safest in acute settings.

Q: A patient is taking an antianginal drug. Which of the following antianginal drugs is contraindicated with sildenafil?

Organic nitrates. **Explanation:** The correct answer is **Organic nitrates** (e.g., Nitroglycerin, Isosorbide dinitrate). **1. Mechanism of Interaction (The "Why"):** Organic nitrates act by releasing **Nitric Oxide (NO)**, which stimulates the enzyme **Guanylyl Cyclase**. This increases levels of **cyclic Guanosine Monophosphate (cGMP)**, leading to smooth muscle relaxation and vasodilation. **Sildenafil** (a PDE-5 inhibitor) prevents the breakdown of cGMP. When taken together, there is a synergistic accumulation of cGMP, leading to profound, unpredictable systemic vasodilation and **severe refractory hypotension**, which can result in myocardial infarction or death. **2. Analysis of Incorrect Options:** * **A. Calcium Channel Blockers (CCBs):** While both CCBs and sildenafil cause vasodilation, they do not share the same biochemical pathway (cGMP). They can be used together with caution, though blood pressure should be monitored. * **B. Beta-adrenergic Blockers:** These drugs decrease heart rate and contractility. There is no direct contraindication or dangerous synergistic effect with PDE-5 inhibitors. * **D. ACE Inhibitors:** These affect the Renin-Angiotensin-Aldosterone System (RAAS). While they lower blood pressure, they do not interact lethally with the NO-cGMP pathway. **3. High-Yield Clinical Pearls for NEET-PG:** * **Time Gap:** Sildenafil should not be taken within **24 hours** of a nitrate dose; Tadalafil (due to a longer half-life) requires a gap of at least **48 hours**. * **Management:** If a patient on sildenafil develops chest pain, nitrates must be avoided. Morphine or non-nitrate vasodilators are preferred. * **Other PDE-5 Inhibitors:** Vardenafil and Tadalafil share this same absolute contraindication with nitrates. * **Alpha-blockers:** Use caution when combining sildenafil with alpha-blockers (like Tamsulosin) due to the risk of additive orthostatic hypotension.

Question 1

All of the following statements about ticlopidine are true except?

Accepted Answer

Directly interacts with platelet membrane glycoprotein IIb/IIIa receptors.

Answer

Onset of action is delayed.

Answer

Duration of action is long.

Answer

It is used as an alternative to aspirin in patients with cerebrovascular disease.

Question 2

Which antihypertensive drug class causes a decrease in Angiotensin II levels?

Accepted Answer

Enalapril

Answer

Hydralazine

Answer

Methyldopa

Answer

Nitroglycerine

Question 3

What is the intravenous treatment for Torsades de pointes?

Accepted Answer

Magnesium

Answer

Sodium bicarbonate

Answer

Saline

Answer

Glucose

Question 4

A 66-year-old patient with congestive heart failure (CHF) deviates from his low-salt diet while traveling. Five days later, he presents with severe shortness of breath and significant pulmonary edema. What is the first-line drug of choice for this patient?

Accepted Answer

Furosemide

Answer

Dobutamine

Answer

Metoprolol

Answer

Spironolactone

Question 5

All of the following are ECG changes seen in Digoxin toxicity except?

Accepted Answer

PR shortening

Answer

QT shortening

Answer

ST depression

Answer

T wave inversion

Question 6

Which of the following drugs should not be used empirically in the management of isolated systolic hypertension in the elderly?

Accepted Answer

Prazosin

Answer

Enalapril

Answer

Amlodipine

Answer

Chlorthalidone

Question 7

Which of the following statements about ezetimibe is true?

Accepted Answer

Inhibitor of NPCIL 1

Answer

Cholesteryl ester transfer protein inhibitor

Answer

PPAR alpha inhibitor

Answer

Inhibitor of PPAR Gamma

Question 8

A 69-year-old man with heart failure and paroxysmal atrial fibrillation is prescribed amiodarone for maintenance of sinus rhythm. Which of the following is a known characteristic of amiodarone?

Accepted Answer

An active metabolite

Answer

Excellent oral absorption

Answer

A short half-life

Answer

Few drug interactions

Question 9

Which beta-blocker can be safely used in hepatic disease?

Accepted Answer

Esmolol

Answer

Betaxolol

Answer

Bisoprolol

Answer

Carvedilol

Question 10

A patient is taking an antianginal drug. Which of the following antianginal drugs is contraindicated with sildenafil?

Accepted Answer

Organic nitrates

Answer

Calcium channel blockers

Answer

Beta-adrenergic blockers

Answer

Angiotensin-converting enzyme inhibitors

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?